Background: Administering an abbreviated global cognitive test, such as the Montreal Cognitive Assessment (MoCA), is necessary for the recommended first-level diagnostic criteria for mild cognitive impairment (MCI) in Parkinson's disease (PD). Level II requires administering cognitive functioning neuropsychological tests. The MoCA's suitability for identifying PD-MCI is questionable and, despite the importance of cognitive deficits reflected through daily functioning in identifying PD-MCI, knowledge about it is scarce. Objectives: To explore neuropsychological test scores of patients with PD who were categorized based on their MoCA scores and to analyze correlations between this categorization and patients’ self-reports about daily functional-related cognitive abilities. Methods: A total of 78 patients aged 42 to 78 years participated: 46 with low MoCA scores (22–25) and 32 with high MoCA scores (26–30). Medical assessments and level II neuropsychological assessment tools were administered along with standardized self-report questionnaires about daily functioning that reflects patients’ cognitive abilities. Results: A high percentage of the low MoCA group obtained neuropsychological test scores within the normal range; a notable number in the high MoCA group were identified with MCI-level scores on various neuropsychological tests. Suspected PD-MCI according to the level I criteria did not correspond well with the level II criteria. Positive correlations were found among the 3 self-report questionnaires. Conclusions: These results support the ongoing discussion of the complexity of capturing PD-MCI. Considering the neuropsychological tests results, assessments that reflect cognitive encounters in real life daily confrontations are warranted among people diagnosed with PD who are at risk for cognitive decline.
|Number of pages||8|
|Journal||Movement Disorders Clinical Practice|
|State||Published - 1 Aug 2020|
Bibliographical noteFunding Information:
This study was funded by a grant provided by the Israeli Ministry of Science and Technology (3‐13719). The authors declare that there are no conflicts of interest relevant to this work.
This study was funded by a grant provided by the Israeli Ministry of Science and Technology (3-13719). The authors declare that there are no conflicts of interest relevant to this work. This study was approved by the ethics committee of the Sheba Medical Center. Written declaration of patient consent was obtained from each participant and documented. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. This study was funded by a grant provided by the Israeli Ministry of Science and Technology (3-13719). The authors declare that there are no conflicts of interest relevant to this work. S.R. reports a National Insurance grant and an Insurance Companies Association grant. S.I.K. reports Medison. G.Y. reports AbbVie. S.H. reports a National Insurance grant and an Insurance Companies Association grant and AbbVie, Teva, and Medison. S.M., N.G., L.M., A.R., V.L., T.F.K., and T.N. declare that there are no additional disclosures to report.
© 2020 International Parkinson and Movement Disorder Society
- Parkinson's disease
- daily functioning
- mild cognitive impairment
ASJC Scopus subject areas
- Clinical Neurology